Interleukin-2 (IL2)

Phase 2Protein / enzyme

Astellas

Interleukin-2 (IL2) is one of 134 small molecule programs targeting Efficacy and Safety. It is currently in Phase 2.

Indications

Total Trials

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

Efficacy and SafetyNot yet recruiting

Pleural EffusionNot yet recruiting

Pancreatic CancerNot yet recruiting

Renal Cell CarcinomaRecruiting

Efficacy and SafetyPhase 2

Not yet recruiting

Pleural EffusionPhase 1

Not yet recruiting

Pancreatic CancerPhase 2

Not yet recruiting

Renal Cell CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Interleukin-2 (IL2)

Astellas

Phase 2

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

HS-20093

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Preclinical

1 10

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Non-Small Cell Lung Cancer

NCT05681780

Q2 2028

Phase 2Not yet recruiting

Pancreatic Cancer

NCT05810792

Q3 2031

Phase 1Recruiting

Renal Cell Carcinoma

NCT06318871

Q1 2038

Phase 1Not yet recruiting

Pleural Effusion

NCT07443020

Clinical

Trials by Indication[1]

Melanoma3 trials

Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT00204581·51 enrolled

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00059475·138 enrolled

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Withdrawn·JJames Isaacs, MD·Phase 1·NCT06190249

Non-Small Cell Lung Cancer2 trials

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03215810·20 enrolled

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05681780·20 enrolled

Atherosclerotic Plaque1 trial

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.

Active, not recruiting·—·N/A·NCT05975554·30 enrolled

Dendritic Cell1 trial

Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00176761·27 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT06971913·100 enrolled

9 more indications

Pleural effusion1 trial

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

Not yet recruiting·—·Phase 1·NCT07443020·10 enrolled

Cell Therapy1 trial

The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial

Completed·UUniversity Health Network, Toronto·Phase 1·NCT03158935·8 enrolled

Pancreatic Cancer1 trial

Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer

Not yet recruiting·SSahlgrenska University Hospital·Phase 2·NCT05810792·50 enrolled

Renal Cell Carcinoma1 trial

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Recruiting·—·Phase 1·NCT06318871·10 enrolled

Acute Coronary Syndrome1 trial

Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY

Completed·—·Phase 2·NCT04241601·60 enrolled

Hematologic Malignancies1 trial

Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00697671·48 enrolled

Interleukin1 trial

Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00113282·57 enrolled

Gastric Cancer1 trial

Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer

Completed· Astellas logo

Astellas·Phase 1·NCT01671774·29 enrolled

Kidney Cancer1 trial

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

Withdrawn·LLoma Linda University·Phase 2·NCT01355562

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Interleukin-2 (IL2). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Interleukin-2 (IL2) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Interleukin-2 (IL2). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: Astellas

Interleukin-2 (IL2)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q3 2031

Q1 2038

Trials by Indication[1]

Melanoma3 trials

Non-Small Cell Lung Cancer2 trials

Atherosclerotic Plaque1 trial

Dendritic Cell1 trial

Efficacy and Safety1 trial

Pleural effusion1 trial

Cell Therapy1 trial

Pancreatic Cancer1 trial

Renal Cell Carcinoma1 trial

Acute Coronary Syndrome1 trial

Hematologic Malignancies1 trial

Interleukin1 trial

Gastric Cancer1 trial

Kidney Cancer1 trial

References

Drug Info

Quick Facts

Related News